Table 1.
Baseline cohort characteristics for phase 1b trials.
| Study | Chow et al. 2017 [12] | Shayan et al. 2018 [13] | Machiels et al. 2013 [14] * |
|---|---|---|---|
| Agent | Motolimod | Motolimod | IMO-2055 |
| Treatment | Motolimod + cetuximab | Motolimod + cetuximab | IMO-2055 + 5-fluorouracil, cisplatin, and cetuximab |
| Patient Population | R/M HNSCC | Untreated HNSCC | R/M HNSCC |
| Number of Patients | 13 | 14 | 13 |
| Median Age | 62 | 61 | 59 |
| ECOG | |||
| 0 (%) | 15 | - | 62 |
| 1 (%) | 70 | - | 38 |
| ≥2 (%) | 15 | - | 0 |
| Sex | |||
| Male (%) | 77 | 64 | 92 |
| Female (%) | 23 | 36 | 8 |
| Tumor Site | |||
| Oral cavity (%) | 15 | 71 | 38 |
| Oropharynx (%) | 46 | 7 | 38 |
| Larynx (%) | 23 | 14 | 8 |
| Hypopharynx (%) | 8 | 7 | 15 |
| Other (%) | 8 | 0 | 0 |
| HPV Status | |||
| Positive (%) | 23 | - | - |
| Negative (%) | 8 | - | - |
| Unknown (%) | 70 | - | - |
| Prior Treatment | |||
| Chemotherapy (%) | 77 | - | 69 |
| Radiation (%) | 92 | - | 100 |
| Surgery (%) | 70 | - | 77 |
| Cetuximab (%) | 77 | - | - |
| Recurrence Type | |||
| Locoregional (%) | 8 | - | 31 |
| Distant Metastasis (%) | 46 | - | 69 |
| Both (%) | 46 | - | 0 |
* Trial terminated early for safety concerns.